Peter Špalek
Frovatriptan is a selective 5HT1B/1D receptor agonist for management of migraine attacks in patients from 18 to 65 years.
Frovatriptan has a long half-time (26 h), five times longer in comparison to other triptans and low incidence of migraine
recurrence. Frovatriptan is indicated for the acute treatment of migraine with or without aura, and has a very good
safety and tolerability profile. Several studies have shown that a 6-day regimen of frovatriptan scheduled during the perimenstrual
period significantly reduced the incidence and severity of menstrual migraine (attacks that regularly start
day -2 to +3 relative to menses). Prevention may be important because menstrual migraine attacks have been characterized
as being of longer duration, more severe and more refractory to treatment than non-menstrual migraine attacks.